Clarus Therapeutics Holdings, Inc.

Informe acción OTCPK:CRXT.Q

Capitalización de mercado: US$57.2k

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Salud financiera de hoja de balance de Clarus Therapeutics Holdings

Salud financiera controles de criterios 0/6

Información clave

-310.1%

Ratio deuda-patrimonio

US$40.51m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$19.17m
Patrimonio-US$13.06m
Total pasivoUS$62.00m
Activos totalesUS$48.94m

Actualizaciones recientes sobre salud financiera

Recent updates

Clarus Therapeutics GAAP EPS of -$0.24 beats by $0.06, revenue of $4.05M misses by $0.92M

Aug 18

Clarus Therapeutics: Advancing Androgen Replacement And Metabolic Therapies

Dec 01

Análisis de la situación financiera

Pasivos a corto plazo: CRXT.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Pasivo a largo plazo: CRXT.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Historial y análisis de deuda-patrimonio

Nivel de deuda: CRXT.Q has negative shareholder equity, which is a more serious situation than a high debt level.

Reducción de la deuda: CRXT.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CRXT.Q has less than a year of cash runway based on its current free cash flow.

Pronóstico de cash runway: CRXT.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.6% each year


Descubre empresas con salud financiera